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Upregulated IL-1β in dysferlin-deficient
muscle attenuates regeneration by blunting
the response to pro-inflammatory macrophages
Tatiana V. Cohen1,2,3* , Gina M. Many1, Bryan D. Fleming4, Viola F. Gnocchi1, Svetlana Ghimbovschi1,
David M. Mosser4, Eric P. Hoffman1 and Terence A. Partridge1

Abstract
Background: Loss-of-function mutations in the dysferlin gene (DYSF) result in a family of muscle disorders known
collectively as the dysferlinopathies. Dysferlin-deficient muscle is characterized by inflammatory foci and macrophage
infiltration with subsequent decline in muscle function. Whereas macrophages function to remove necrotic tissue in
acute injury, their prevalence in chronic myopathy is thought to inhibit resolution of muscle regeneration. Two major
classes of macrophages, classical (M1) and alternative (M2a), play distinct roles during the acute injury process.
However, their individual roles in chronic myopathy remain unclear and were explored in this study.
Methods: To test the roles of the two macrophage phenotypes on regeneration in dysferlin-deficient muscle, we
developed an in vitro co-culture model of macrophages and muscle cells. We assayed the co-cultures using ELISA
and cytokine arrays to identify secreted factors and performed transcriptome analysis of molecular networks induced in
the myoblasts.
Results: Dysferlin-deficient muscle contained an excess of M1 macrophage markers, compared with WT, and
regenerated poorly in response to toxin injury. Co-culturing macrophages with muscle cells showed that M1
macrophages inhibit muscle regeneration whereas M2a macrophages promote it, especially in dysferlin-deficient
muscle cells. Examination of soluble factors released in the co-cultures and transcriptome analysis implicated two
soluble factors in mediating the effects: IL-1β and IL-4, which during acute injury are secreted from M1 and M2a
macrophages, respectively. To test the roles of these two factors in dysferlin-deficient muscle, myoblasts were treated
with IL-4, which improved muscle differentiation, or IL-1β, which inhibited it. Importantly, blockade of IL-1β signaling
significantly improved differentiation of dysferlin-deficient cells.
Conclusions: We propose that the inhibitory effects of M1 macrophages on myogenesis are mediated by IL-1β signals
and suppression of the M1-mediated immune response may improve muscle regeneration in dysferlin deficiency. Our
studies identify a potential therapeutic approach to promote muscle regeneration in dystrophic muscle.
Keywords: Skeletal muscle, Myoblasts, Macrophages, Cell-cell interactions, Muscular dystrophy, Dysferlin, LGMD2B
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Background
A spectrum of distinct myopathies is associated with mutations in the protein dysferlin [1]. The most common
manifestations include limb-girdle muscular dystrophy 2B
(LGMD2B), an autosomal recessive myopathy marked by
proximal muscle weakness, with an onset in the late teens
([2, 3], reviewed in [4]) and Myoshi myopathy, characterized by a progressive muscle wasting involving distal muscles ([5] reviewed in [4]). In general, these myopathies
feature chronic regeneration and fibrosis [6], a selective
loss of type 2 muscle fibers and a moderate degree of inflammation surrounding the necrotic fibers [7], although
the severity of pathology is variable. Additionally, tissue
pathology is focal and sporadic, making dysferlinopathy a
challenging disorder to characterize, diagnose, and treat.
Dysferlin-deficient muscle is characterized by inflammatory foci that consist of necrotic fibers and infiltrating
immune cells. Myofibers undergoing necrosis release
danger-associated molecular patterns (DAMPs) that activate innate immune receptors resulting in release of cytokines and chemokines and subsequent recruitment of
inflammatory cells that remove the necrotic debris and
facilitate muscle regeneration [8]. The primary infiltrating cells in dystrophic muscle are macrophages, which
have been studied more extensively in the mdx mouse
model of Duchenne muscular dystrophy [9].
Macrophages have been classified into two major categories: the classically activated (M1) and the alternatively
activated (M2a). M1 macrophages, identified by expression and secretion of TNFα, Cox-2, IL-1β, IL-12, and
iNOS, respond to TLR ligands such as lipopolysaccharide
(LPS) and demonstrate phagocytic and bacteriocidal activity [10]. In contrast, M2a macrophages, identified by expression of mannose receptor (Mrc1), resistin-like α
(Retnla, Fizz1), and chitinase 3-like 3 (Chi3l3, Ym1), are
activated by IL-4 or IL-13 signals that arise during Th2
immune responses and participate in wound-healing processes (reviewed in [11, 10]). Immune cells are sequentially recruited to sites of acute injury, with a wave of
neutrophils followed by M1-polarized macrophages that
phagocytose necrotic material. M2a macrophages are also
recruited at the time of M1 macrophage infiltration [12]
and remain at the site of injury as M1 macrophages transdifferentiate to M2a macrophages in situ [13, 14], thereby
resolving the injury and promoting myoblast differentiation. Studies of the macrophage populations in mdx mice
determined that M1 macrophages predominate during
early phases to be replaced by M2a macrophages during
the later regenerative/fibrotic stages of the disease [15].
Additionally, regulatory macrophages, M2b, are a third
category of macrophages and are characterized by IL-10
secretion and anti-inflammatory activity.
The effects of the two types of differentially polarized
macrophages on muscle cells were previously studied in
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the context of wild-type muscle [16]. Direct co-culture of
myoblasts with M2 macrophages, or conditioned medium
from them, increased myogenin-positive cells and myotubes, whereas co-culture or conditioned medium from M1
macrophages had no effect [16], whereas other studies have
suggested that M1 macrophages promote myoblast proliferation and M2a promote myotube fusion [14]. These studies implicate macrophages as playing a major role in the
process of muscle regeneration. However, the role of macrophages in chronic myopathies remains to be elucidated.
To examine myoblast-macrophage interactions, we used
an in vitro co-culture system of macrophages and immortalized myoblasts (H-2K cells), focusing on the molecular
effects of macrophage-released soluble factors on myoblasts. We hypothesized that macrophage-secreted factors
can influence differentiation of dysferlin-deficient muscle
and proceeded to identify such factors and examine their
effects on myoblasts. To approach these questions, we (1)
examined the effects of co-culture with M1 and M2a macrophages on the differentiation of wild-type (WT) mouse
myoblasts, (2) compared the effects of macrophages in
dysferlin-deficient dystrophic myoblasts, and (3) identified
IL-1β as the M1-derived factor inhibiting muscle differentiation in dysferlin deficiency. Importantly, we show for
the first time that use of a blocking antibody to inhibit IL1β improves muscle differentiation in dysferlin-deficient
myotubes. Our studies delineate the effects of the proinflammatory environment on muscle regeneration in dysferlinopathy and raise the possibility of modulating this
environment to promote muscle regeneration.

Methods
Animals

All animal protocols were reviewed and approved by the
local Institutional Animal Care and Use Committee of
the Children’s National Medical Center, Washington, DC.
Four- to seven-month-old Bla/J mice (B6.A-Dysfprmd/
GeneJ) (stock # 012767) and BALB/c (stock# 000651)
were obtained from The Jackson Laboratory (Bar Harbor,
ME). The Bla/J model of dysferlin deficiency, produced by
crossing the A/J naturally occurring dysferlin-mutated
mice onto the C57Bl6/J background, was previously characterized as having moderate inflammation and pathology,
making it a suitable murine model for human disease and
one that has good strain-specific controls [17]. Mice were
euthanized by CO2 asphyxiation followed by cervical dislocation, and muscles were flash frozen in melting isopentane (Fisher) cooled in liquid nitrogen.
Notexin injury

Notexin is a myotoxic phospholipase A2 derived the
venom of the Australian tiger snake (Notechis scutatus).
Four- to seven-month-old Bla/J and C57Bl/6J male mice
were anesthetized by isoflurane inhalation, and the
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hindlimbs were shaved. A unilateral injection of 20 μl of
notexin (10 μg/ml; Latoxan, Valence, France) was delivered into the tibialis anterior (TA) muscle, with the
contralateral leg used as an uninjected control. To identify injured muscles, tattoo ink at a concentration of 1:6
v/v was included in the notexin solution. To mark proliferating cells, 5′bromo-2′deoxyuridine (BrdU, Sigma, St.
Louis, MO) at 0.8 mg/ml was administered in the drinking water for 1 week from the time of injury and the tissues were harvested at indicated time points.
Bone marrow-derived macrophage culture

Bone marrow-derived macrophages were derived as described previously [18] from 6-week-old female BALB/c
mice in all cases except experiments using dysferlindeficient macrophages, which were derived from Bla/J and
C57Bl/6 (WT) mice. Briefly, mice were euthanized, and
the bone marrow was flushed for collection from the central canals of the femur and tibia with phosphate-buffered
saline (PBS) containing 200 U/ml penicillin and 200 μM/
ml streptomycin. The cells were plated for culture in Dulbecco’s modified Eagle medium/Ham’s F-12 Nutrient Mixture (DMEM/F-12, Life Technologies, Grand Island, NY)
containing 10 % fetal bovine serum (FBS), 100 U/ml penicillin and 100 μM/ml streptomycin, and 1 % L-glutamine
(all from Life Technologies) (bone marrow media), supplemented with 15 % L929 cell conditioned media (LCCM)
in a 37 °C and 5 % CO2-humidified incubator. After 7 days
of culture, macrophages were stimulated as previously described to induce classical (M1), alternative (M2a), or
regulatory (M2b) macrophage phenotypes [19]. Nonstimulated macrophages were used as controls (Mϕ). The
stimulation conditions were as follows: (1) M1 activation,
10 ng/ml LPS (Sigma) in LCCM; (2) M2a activation, 20
ng/ml IL-4 (R&D Systems, Minneapolis, MN) in LCCM;
(3) M2b activation, 10 ng/ml LPS plus IgG Ova-immune
complex [20] in LCCM; and (4) non-activated, LCCM
only. The stimulation protocols were terminated by centrifugation and careful rinsing with PBS to remove all
stimulation media. The differentially polarized macrophages were re-suspended in DMEM containing 5 %
horse serum, 2 % chick embryo extract (US Biological,
Salem, MA), 100 U/ml penicillin, and 100 μM/ml streptomycin (differentiation media). The activated macrophages
were validated by quantitative real-time polymerase chain
reaction (qRT-PCR) and/or enzyme-linked immunosorbent assay (ELISA) for M1 markers IL-12, TNFα, and iNOS
and M2a markers Fizz-1 and IL-4 [18] (Fig. 1).
H-2K myoblast-macrophage co-culture

Immortalized H-2K myoblasts derived from crosses of
Immortomice® with WT and A/J mice were previously
described [21]. Myoblasts were maintained in DMEM
containing 20 % heat-inactivated FBS, 2 % chick embryo
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extract, 100 U/ml penicillin and 100 μM/ml streptomycin,
and 0.2 % IFNγ (R&D Systems) (proliferation medium).
For co-culture differentiation experiments, myoblasts
were plated onto Matrigel™ (BD Biosciences, San Jose,
CA)-coated 6-well dishes at a density of 5 × 104/cm2 and
incubated at 33 °C and 10 % CO2. The next day (day 1 of
co-culture), media was changed to differentiation media,
lacking IFNγ. In parallel, the differentially polarized macrophages re-suspended in differentiation media were
plated onto 0.4-μm Transwell™ inserts (Corning #3412,
Tewksbury, MA) at 1.5 × 106 cells/insert on top of the
myoblasts and the co-cultures were maintained at 37 °C
and 5 % CO2. Supernatants were collected, and myotubes
were harvested at indicated days of differentiation. All experiments were performed in triplicate.
For cytokine treatments and IL-1β blocking experiments, myoblasts were plated on glass cover slips in 6well dishes at 0.2 × 105 cells/cm2. After an overnight
incubation, medium was changed to differentiation
medium containing indicated concentrations of IL-4
(PeproTech, Rocky Hill, NJ), IL-1β (R&D Systems), or
IL-1β mAb (MM425B, Thermo, Rockford, IL) (day 1).
To control for specificity of the blocking antibody, cultures were treated with equimolar concentrations of
mouse IgG (Vector Laboratories, Burlingame, CA). Cultures were incubated for three additional days, and then
differentiated muscle cells were fixed and immunostained as described below.
Gene arrays and qRT-PCR

Illumina® Gene arrays were performed on differentiated myoblasts either cultured without macrophages
(untreated) or co-cultured with M1 or M2a macrophages for 3 days. All experiments were performed in
triplicate. Total RNA was extracted using the Trizol™
reagent (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions. Concentration of each RNA
sample was determined using a NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington,
DE). The quality of RNA samples was assessed using the
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa
Clara, CA).
A 200-ng aliquot of high-quality total RNA from each
sample was applied for mRNA expression profiling
using Illumina® Gene Expression BeadChip Array technology (Illumina, Inc., San Diego, CA). Reverse transcription of the first and synthesis of the second cDNA
strands, followed by a single in vitro transcription
(IVT) amplification that incorporates biotin-labeled nucleotides, were performed using the Illumina® TotalPrep™-96 RNA Amplification Kit (Ambion, Austin, TX).
Of the biotin-labeled IVT product (cRNA), 1.5-μg was
hybridized to MouseWG-6v2_BeadChip (Illumina, Inc.,
San Diego, CA) for 16 h, followed by washing, blocking,
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Fig. 1 Characterization of M1 and M2 macrophages in response to differential stimuli. Bone marrow-derived macrophages were either unstimulated
(Mϕ), stimulated with LPS, to induce M1, or IL-4 to induce the M2a phenotypes, respectively. a M1 phenotype validation using qRT-PCR
for IL-12, b TNFα, and c iNOS. d ELISA analysis for IL-12/23p40 in M1, M2a, or control (Mϕ) macrophages. e Gene expression of Fizz-1 by
qRT-PCR in M1, M2a, or control (Mϕ) macrophages. f Gene expression of IL-4 by qRT-PCR in M1, M2a, or control (Mϕ) macrophages

and streptavidin-Cy3 staining according to the WholeGenome Gene Expression Direct Hybridization protocol
(Illumina, Inc., San Diego, CA). The arrays were scanned
using HiScanSQ System, and decoded images were analyzed by GenomeStudio™ Gene Expression Module—an
integrated platform for data visualization and analysis
(Illumina, Inc., San Diego, CA). GenomeStudio-generated
final report table was used in Hierarchical Clustering Explorer software (HCE v3) for filtering, power analysis, and
chip-based unsupervised clustering [22].
Significant molecular networks and transcriptional regulators were identified using Ingenuity Pathway Analysis
(IPA) software (Ingenuity Systems, Inc., Redwood City,
CA). IPA generates networks in which differentially regulated genes can be related according to previously known
associations between genes or proteins—the higher the
score, the more supportive data is found in the previously
published literature (IPA database). Additionally, we used
IPA to calculate the z-score to determine expression
direction of the transcriptional networks. A z-score >1.5
or <1.5 indicated upregulated or downregulated transcriptional networks, respectively.

qRT-PCR for indicated genes (Table 1) was performed
using SYBR® Green PCR Master Mix (Applied Biosystems, Grand Island, NY) on an Applied Biosystems
7900HT Fast Real-Time PCR System. Relative gene expression was determined from absolute Ct values using
the ΔΔCt method by normalizing to housekeeping
genes, S18 and GAPDH.
Histology and immunofluorescence microscopy

Frozen 10-μm muscle sections were stained with
hematoxylin and eosin (H&E) as previously described
[23]. For immunofluorescence labeling, sections were
fixed with 4 % paraformaldehyde (PFA) and nonspecific antibody binding was blocked with a solution
containing 20 % normal goat serum, 2 % bovine serum
albumen, 0.5 % Triton-X-100, and 0.1 % Tween-20.
Sections were incubated with a pan-specific macrophage antibody, F4/80 (AbD Serotec, Raleigh, NC),
followed by Alexa 488-conjugated anti-rat secondary
antibody. BrdU immunostaining was performed with
anti-BrdU (Invitrogen) and anti-laminin (Sigma) antibodies and propidium iodide (PI) to visualize nuclei, as
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Table 1 qRT-PCR primers used in the study
Forward

Reverse

Arg-1

5′-ATGGAAGAGACCTTCAGCTAC-3′

5′-GCTGTCTTCCCAAGAGTTGGG-3′

CCR2

5′-ACACCCTGTTTCGCTGTAGG-3′

5′-CCTGGAAGGTGGTCAAGAAG-3′

Fizz-1

5′-TCCCAGTGAATACTGATGAGA-3′

5′-CCACTCTGGATCTCCCAAGA-3′

Ifng

5′-CATTGAAAGCCTAGAAAGTCTG-3′

5′-CTCATGGAATGCATCCTTTTTCG-3′

IL-1β

5′-TGGGCCTCAAAGGAAAGAAT-3′

5′-CAGGCTTGTGCTCTGCTTGT-3′

IL-4

5′-CATCGGCATTTTGAACGAGGTCA-3′

5′-CTTATCGATGAATCCAGGCATCG-3′

IL-10

5′-CCAGTTTTACCTGGTAGAAGTGATG-3′

5′-TGTCTAGGTCCTGGAGTCCAGCAGAC-3′

IL-12

5′-ATGGCCATGTGGGAGCTGGAG-3′

5′-TTTGGTGCTTCACACTTCAGG-3′

Inos

5′-TGGGAATGGAGACTGTCCCAG-3′

5′-GGGATCTGAATGTGATGTTTG-3′

MCP-1

5′-AGGTCCCTGTCATGCTTCTG-3′

5′-GCTGCTGGTGATCCTCTTGT-3′

Myf5

5′-GCTCGGATGGCTCTGTAGAC-3′

5′-GAACAGCAGCTTTGACAGCA-3′

MyoD

5′-GGCTACGACACCGCCTACTA-3′

5′-GCTCCACTATGCTGGACAGG-3′

Myogenin

5′-CTGACCCTACAGACGCCCAC-3′

5′-TGTCCACGATGGACGTAAGG-3′

TNFa

5′-GTTCTATGGCCCAGACCCTCACA-3′

5′-TCCCAGGTATATGGGCTCATACC-3′

YM-1

5′-GGGCATACCTTTATCCTGAG-3′

5′-CCACTGAAGTCATCCATGTC-3′

S18

5′-TAGCCTTCGCCATCACTGCC TTA-3′

5′-AACCTGGCTGTACTTCCCATCCTT-3′

previously described [23]. Quantitation of BrdUpositive nuclei was performed in notexin-lesioned muscles (n = 3 mice per time point). Injured muscle sections were visually examined, and 20× images of the
lesion epicenter were acquired. Percent BrdU-positive
nuclei were calculated by expressing BrdU-positive nuclei as a percentage of total PI-positive nuclei.
Differentiated muscle cells from co-cultures or
treatments with indicated cytokines were fixed with
4 % PFA, permeabilized in 0.5 % Triton-X 100/PBS,
blocked in 5 % horse serum, and incubated overnight
with anti-MyoD (Novus, Littleton, CO) and antiMyHC (MF20, Developmental Studies Hybridoma
Bank, Iowa City, IA) antibodies. The next day, cultures
were washed in 0.1 % Triton-X 100/PBS and stained
with AlexaFluor® 488-tagged goat anti-rabbit and
AlexaFluor® 568-tagged goat anti-mouse secondary
antibodies for 1 h at room temperature. Samples were
mounted in 4′,6-diamidino-2-phenylindole (DAPI)containing mounting medium (Vector Laboratories).
Desmin immunostaining was performed with the ABC
Elite kit (Vector Laboratories) and counterstained
with eosin. Myotube fusion was expressed as the number of nuclei in myotubes as a percent of total nuclei
in the culture.
Immunofluorescence and histology micrographs were
captured at ambient temperature using a Zeiss M2 AxioImager upright epifluorescence microscope using 10×/0.45
N.A. and 20×/0.8 N.A. objectives and an Axiocam Mrm
CCD camera. Images were acquired using Axiovision 4.8.2
software and analyzed using ImageJ software (National Institute of Health, Bethesda, MD) [24].

Cytokine analysis

ELISAs were performed on culture supernatants using
the Mouse IL-12/IL-23 p40 Non-allele-specific and
Mouse IL-10 Quantikine ELISA kits (R&D Systems)
according to manufacturer’s instructions. Cytokine arrays were performed on 1 ml of supernatant from the
co-cultures using the Mouse Cytokine Antibody array,
Panel A (R&D Systems), according to manufacturer’s
instructions. IL-1β and IL-4 analysis of 24-h coculture supernatants was performed using the MSD
Mouse V-PLEX Proinflammatory Panel 1 kit (Meso
Scale Diagnostics, Rockville, MD). Briefly, biological
triplicates of cell-free supernatants were run in duplicate and analyzed on a QuickPlex SQ120 analyzer
using MSD Discovery Workbench 4.0 software (Meso
Scale Diagnostics, Rockville, MD). Assay sensitivity
using this platform is 0.04 pg/ml.
Whole cell lysates from differentiated muscle cultures
were prepared using the NP40 Lysis buffer (Invitrogen)
containing anti-proteases (Mini-Complete, Roche, Indianapolis, IN). Protein concentration was determined
by the bicinchoninic acid assay (BCA) (Thermo Fisher,
Waltham, MA). To assay for IL-1β, 240-ng protein per
well was assayed in biological triplicates using the
Mouse IL-1β Quantikine ELISA kit (R&D Systems).
Western blotting

Protein concentration was determined by the BCA
assay and 10-μg of protein was resolved on a 4–12 %
Bis-Tris SDS-PAGE gel (Life Technologies) and transferred to PVDF membrane (Bio-Rad). Immunoblotting
was performed using anti-phosphorylated NFκB p65
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subunit (Cell Signaling Technology, Danvers, MA) and
anti-vinculin (Sigma) antibodies diluted in 5 % Blocking
Reagent (Bio-Rad) in Tris-buffered saline and 0.1%
Tween 20 (TBS-T). After washing with TBS-T, membranes
were probed with horseradish peroxidase-conjugated
goat anti-rabbit secondary antibody (Amersham Biosciences,
Piscataway, NJ). The membranes were then incubated
with ECL Western Blotting Detection reagent (Pierce,
Rockford, IL) and processed on Kodak BioMax XAR
X-ray film (Fisher). Densitometry was performed using
ImageJ.
Statistical analysis

Statistical analyses were performed using SigmaPlot v.11
(SyStat Software, Chicago, IL). Student’s t test was used
to evaluate statistical significance in all analyses where
two groups were compared. Unless otherwise specified,
two-way analysis of variance (ANOVA) with Tukey post
hoc analysis was used to compare more than two experimental groups. Data are presented as means ± standard
error of the mean (SEM). P value of <0.05 was considered significant.
For gene array analyses, GenomeStudio mRNA expression values were automatically uploaded (plug-in) into
Partek software (Partek Inc., St. Louis, MO) for statistical analyses and data visualization. During this transaction, Partek automatically applies the robust multi-array
average (RMA)—a normalization algorithm—and performs a log2 transformation for the generated expression
values. One-way ANOVA was applied to verify significance of the comparative results. Only expression values
with fold change ≥1.5 and a P value cut-off of ≤0.01
were considered for the further analyses.

Results
Chronic macrophage infiltration in dysferlin-deficient
muscle attenuates regeneration

Dysferlin-deficient muscle contains inflammatory foci
consisting primarily of mononuclear infiltrate [25]. To
establish a baseline for our studies, we initially validated
the published extent of inflammation and ongoing regeneration in adult (4–7-month-old) Bla/J and C57BL6/J
(WT) mice using in vivo incorporation of the thymidine
analog, BrdU, over a 1-week period to assess the overall
cellular proliferation. At this age, Bla/J muscle contained
significantly more proliferating cells than WT muscle,
(14.0 ± 3.17 vs. 3.0 ± 0.2% P < 0.05) (Fig. 2a, b). Of these,
50 ± 14.0 % of the total BrdU-positive cells in Bla/J
muscle were central myonuclei, the rest being interstitial, indicating that both muscle and inflammatory cells
were proliferating. In contrast, the few BrdU-positive
cells in WT muscle were all interstitial. We next
counted resident macrophages in frozen tissue sections,
identified by F4/80 immunoreactivity, and determined

Page 6 of 21

them to be 65.9 ± 15.5 F4/80-positive cells/mm2 in Bla/J
vs. 5.5 ± 2.5 in WT (Fig. 2a, c), indicating that, consistent with published observations, uninjured Bla/J muscle
contains excess macrophages [17]. Finally, we examined
uninjured Bla/J muscle for M1 (Mcp1, Ifng, Il1b, Tnfα)
and M2 (Ym1, Il10, Arg1, Fizz1, IL-4, and CCR2)-specific
markers. We observed a significant increase in the expression level of MCP1 and IL-1β genes (P < 0.05) in
Bla/J muscle, suggesting increased accumulation of M1
macrophages (Fig. 2d). We further observed that
whereas the expression level of the Ym1 gene, a marker
of M2a macrophages was significantly increased in Bla/J
muscle, the expression level of the IL-10 gene, a marker
of M2b/c macrophages was not significantly increased
above age-matched WT muscle (Fig. 2e). These data
suggest that both M1 and M2a macrophages constitute
the major infiltrating macrophage phenotypes in 4–7month-old dysferlin-deficient muscle.
Enhanced NFκB signaling and inflammation has been
shown to inhibit muscle growth and differentiation [26, 27],
suggesting that chronic inflammatory processes in
dysferlin-deficient muscle impede successful regeneration.
To determine how the presence of chronic inflammatory
macrophages affects the response to injury, we used the
snake venom notexin, a potent and widely used myotoxin [28], to induce muscle injury in 4–7-month-old
Bla/J and WT mice. Injection of notexin resulted in a
robust regenerative response to injury in WT mice,
followed by appearance of centrally nucleated regenerated fibers by day 7 post-injury. Although centrally
nucleated regenerated fibers were also apparent in
Bla/J muscle, they were of smaller cross-sectional area
(CSA) than WT (Fig. 3a, b), with the fiber diameter
distribution shifted to the left, indicating a delay in
regeneration. Cellular proliferation in response to injury was evaluated using BrdU incorporation, administered in drinking water for 1 week following injury.
Analysis of BrdU incorporation in frozen sections revealed BrdU-positive nuclei, which could be detected
by day 3, with peak incorporation observed by day
11. At this time point, 51 ± 6% of nuclei were BrdUpositive in WT muscle, whereas only 23 ± 8% of nuclei were BrdU-positive in dysferlin-deficient muscle
(Fig. 3c, d). Moreover, assessment of F4/80-positive
inflammatory macrophages in the frozen muscle sections showed a robust regenerative response in WT
muscle with a peak on day 3 of, on average, 645.8 ±
10.4 cells/mm2, followed by a rapid reduction in the
infiltrate to an average of 20.8 ± 6.9 cells/mm2 by day
24 (Fig. 3e, f ). The regenerative response in dysferlindeficient muscle was attenuated and prolonged, reaching a peak on day 7 with only 319.4 ± 20.8 cells/
mm2. By day 24, the F4/80-positive cell count
remained elevated in Bla/J muscle with 118.0 ± 24.3
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Fig. 2 Ongoing satellite cell proliferation and macrophage infiltrate in uninjured Bla/J muscle. a Immunofluorescence staining of uninjured
3-month-old WT and Bla/J skeletal muscle. Upper panels mice were treated with BrdU in the drinking water for 7 days. Frozen muscle sections
were immunostained with anti-laminin (blue) and anti-BrdU (green) antibodies. Nuclei were detected by propidium iodide (PI, red). Bottom panels
muscle sections were immunostained with an anti-F4/80 (green) antibody and nuclei were detected by DAPI staining (blue). b Proliferating cells
quantitated in WT and Bla/J muscle are shown as percent of myonuclei that are BrdU-positive (proliferating). n = 3 non-overlapping fields from
three mice. c Quantitation of the number of F4/80-positive macrophages in muscle per mm2. n = 3 non-overlapping fields each from three mice.
d Expression of M1-specific markers using qRT-PCR in WT (black) and Bla/J (white) uninjured muscle. e Expression of M2-specific markers in WT
(black) and Bla/J (white) muscle using qRT-PCR. n = 3 mice per data point. Data are shown as means ± SEM. *P < 0.05; **P < 0.01. Scale, 50 μm

cells/mm2 remaining, indicating inadequate resolution
of the injury response (Fig. 3e, f ). The macrophage
response to injury was further studied by examining
gene expression levels of markers of M1 and M2a
macrophages by qRT-PCR throughout the course of
recovery. This profiling study revealed lower gene expression of M1 markers (IFNγ, TNFα and Arg-1) in
Bla/J than in WT muscle on days 0–3 (Fig. 3g–i). In
contrast, gene expression of the M2a macrophage
marker, Ym1, was greater in Bla/J than in WT muscle
(Fig. 3j). These data suggest an attenuated M1, but
not M2a, recruitment in response to injury in Bla/J
muscle.
In vitro model of myoblast and macrophage interactions

Having shown that macrophages have different effects on
WT and dysferlin-deficient muscle, we sought to directly test
their cellular interactions. We recently characterized H-2K
immortalized myoblasts from dysferlin-deficient (A/J)
mice (A/J myoblasts) and demonstrated that intrinsically

upregulated NFκB pathway signaling inhibits their differentiation efficiency compared with immortalized H-2K
muscle cells derived from dysferlin-sufficient (WT) littermates (WT-myoblasts) [21]. To establish the cellular and
molecular effects that macrophage-derived factors exert
on muscle cells, we developed an in vitro co-culture
model of macrophages and myoblasts.
The cellular effects of macrophages on dystrophic
muscle cells have not been characterized previously. Initial experiments with co-plating showed that direct contact with macrophages diminished myoblast viability. To
look for more subtle effects on muscle, we developed a
Transwell co-culture in which only secreted factors are
exchanged. WT or A/J myoblasts were plated onto Matrigel™-coated dishes and, 1 day later, differentiated macrophages were added onto the Transwell inserts (Fig. 4a).
Bone marrow-derived macrophages (Mϕ) were differentiated to induce three macrophage phenotypes: classically activated (M1), alternatively activated (M2a), and
regulatory macrophages (M2b), as previously described
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Fig. 3 Response to injury is attenuated in Bla/J muscle compared with WT. a H&E staining of WT (left) and Bla/J (right) muscle on day 7 after
injury. b Fiber cross-sectional areas (CSA) from WT (black) and Bla/J (white) on day 7 after injury. Fiber diameter distribution of Bla/J muscle is
shifted to the left. Residual tattoo ink (blue staining) can still be seen in the injured Bla/J muscle. c Immunofluorescence staining for BrdU
(green) and laminin (blue) on indicated days following notexin injury in WT or Bla/J TA muscle. Nuclei were detected with propidium
iodide (PI, red). d Quantitation of BrdU-positive nuclei on day 11 after injury shown as percent of BrdU-positive cells over total myonuclei.
e Immunofluorescence staining for F4/80 (green) on indicated days following notexin injury in WT or Bla/J TA muscle. Nuclei were
detected with DAPI (blue). f Number of F4/80-positive macrophages per mm2 on indicated days after injury. n = 3. Expression of
M1-specific markers IFNγ (g) and TNFα (h) and M2-specific markers Arg-1 (i) and YM1 (j) using qRT-PCR on indicated days following injury.
Data are shown as means ± SEM. *P < 0.05. Scale bar, 50 μm

(see the “Methods” section; [19]). Activation of the M1
phenotype was confirmed by increased gene expression
of IL-12 (Fig. 1a), TNFα (Fig. 1b), and iNOS (Fig. 1c) and
secretion of IL12p40 ([19]; Fig. 1d), 24 h after stimulation. Activation of the M2a phenotype was confirmed by
increased expression of Fizz-1 ([18]; Fig. 1e) and IL-4
(Fig. 1f ).

WT M1 macrophages inhibit, while M2a macrophages
potentiate myogenic differentiation of A/J cells

Following 3 days of co-culture, muscle differentiation
was assessed by immunostaining for the muscle-specific
marker, desmin (Fig. 4b). WT myoblasts cultured in the
absence of macrophages differentiated well following the
3-day differentiation period with 57.5 ± 1.4 % nuclei
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Fig. 4 Co-culture of A/J and WT myoblasts with M1 and M2a macrophages. a Diagram of myoblast-macrophage co-cultures. H-2K cells are plated
in a 6-well dish and macrophages are plated in the top TranswellTM chamber. Soluble factors secreted by both macrophages and myoblasts can
be exchanged in the culture medium. b Desmin immunostaining of dysferlin-deficient (A/J, left column) and dysferlin-sufficient (WT, right column)
myoblasts after 3 days of co-culture with differentially polarized macrophages: LPS treated (M1), IL-4 treated (M2a), LPS+OVA-IC treated (M2b), or
untreated (Mϕ). Scale, 50 μm. c % Fusion index in 3-day-old co-cultures of WT and A/J myoblasts with WT mice-derived macrophages obtained
by dividing the number of nuclei in myotubes by total myonuclei. d Total number of cells in 3-day-old co-cultures with WT mice-derived
macrophages. e % Fusion index in 3-day-old co-cultures of WT and A/J myoblasts with Bla/J mice-derived macrophages. n = 3 independent
experiments. Data are shown as means ± SEM; ANOVA, *P < 0.05; ***P < 0.001

being in myotubes (none, Fig. 4c). Differentiation was
lower in A/J myoblasts cultured alone (39.1 ± 1.9 %, P <
0.05), as had been previously reported [21]. Co-culture
of both WT and A/J myoblasts with M1 or M2b macrophages significantly reduced myofusion (Fig. 4c). However, the reduction to myofusion observed in WT
myoblast-M1 macrophage co-cultures (83 % reduction,
from 57.5 ± 1.4 to 9.9 ± 1.8 %) was greater than that

observed in A/J myoblast-M1 macrophage co-cultures
(58 % reduction, from 39.1 ± 1.9 to 16.5 ± 1.6 %)
(Fig. 4c). Total cell numbers of WT and A/J cells were
unaffected by co-culture (Fig. 4d).
Co-culture with M2a macrophages also had different
effects on WT and A/J cells, whereas co-culture with M2a
macrophages significantly increased fusion of A/J myoblasts, without change in total cell numbers (39.0 ± 1.9 vs.
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49.7 ± 2.5 %, P < 0.05) (Fig. 4c, d), such an increase was
not observed in WT myoblast-M2a macrophage cocultures (57.5 ± 1.4 vs. 32.7 ± 2.2 %, P < 0.05). Since none
of these effects resulted from changes to cell numbers
(Fig. 4d), these data suggest that differentiation of A/J
myoblasts is resistant to the anti-myogenic effects of
M1 macrophages, but may be potentiated by the promyogenic effects of M2a macrophages.

medium of WT cells co-cultured with M1 macrophages
revealed expression of pro-inflammatory cytokines IL23, RANTES, and TNFα (Fig. 5c). In contrast, co-culture
with M2a macrophages resulted in secretion of the Th2associated cytokine, IL-4. We further determined the
concentration of IL-4 in the M2a co-cultures to be unchanged between WT and A/J myoblasts (10.6 ± 0.3 vs.
10.6 ± 2.8 pg/ml, respectively) (Fig. 5d).

Dysferlin-deficient M2a macrophages do not potentiate
myogenic differentiation of A/J myoblasts

M1 and M2a macrophages exert different molecular
effects on WT and dysferlin-deficient myoblasts

Dysferlin-deficient murine macrophages were previously
reported to be more phagocytic than WT [29]. We used
the co-culture model to further study the effects of macrophages derived from dysferlin-deficient mice (Bla/J) on
muscle differentiation, compared with macrophages derived from C57Bl/6J mice (WT). WT myoblasts cocultured with unpolarized Bla/J Mϕ macrophages
showed approximately 37 % less myotube fusion (22.0 ±
1.3 %) (Fig. 4e) than those co-cultured with WT Mϕ
macrophages (35.6 ± 3.1 %) (Fig. 4c). Interestingly, such
inhibition of myotube fusion was not observed when A/J
myoblasts were co-cultured with Bla/J Mϕ macrophages.
Furthermore, in contrast to the beneficial effects on A/J
myoblasts of WT M2a macrophage co-culture, their fusion was not improved by co-culture with Bla/J M2a
macrophages (Fig. 4e). Together, these data suggest that
M2a macrophages from Bla/J mice show reduced promyogenic activity.

The co-culture experiments suggested that M1 and
M2a-polarized macrophages can greatly impact the
course of myoblast differentiation, and this activity is
dependent on functional dysferlin both in macrophages
and in myoblasts. To gain insight into the molecular
events orchestrating these effects, we performed Illumina transcriptome analysis on WT and A/J myoblasts
co-cultured for 3 days with M1 or M2a macrophages derived from BALB/c mice (Fig. 6). To identify transcripts
in differentiated muscle cultures regulated specifically by
co-culture with either M1 or M2a macrophages, transcriptome data were normalized to myoblasts cultured
alone (untreated). We identified 2874 transcripts that
were differentially regulated in WT myoblasts cocultured with M1 macrophages and 1112 transcripts that
were differentially regulated in WT myoblasts cocultured with M2a macrophages (P < 0.01) (Fig. 6a).
Venn diagrams showed that, of these, 2350 transcripts
were regulated specifically by WT myoblast-M1 macrophage co-culture, 588 were regulated specifically by WT
myoblast-M2a macrophage co-culture, and 524 transcripts were in common within WT myoblast-M1
macrophage and WT myoblast-M2a macrophage cocultures (Fig. 6a). Interestingly, there were fewer regulated transcripts in A/J myoblasts co-cultured with macrophages: 1743 transcripts were differentially regulated
in A/J myoblast-M1 macrophage co-cultures and 986
transcripts were differentially regulated in A/J myoblastM2a macrophage co-cultures (Fig. 6b). Venn analysis
showed that, of these, 1274 transcripts were regulated
specifically by A/J myoblast-M1 macrophage co-culture,
517 were regulated specifically by A/J myoblast-M2a
macrophage co-culture, and 469 were regulated by both
A/J myoblast-M1 macrophage and A/J myoblast-M2a
macrophage co-cultures (P < 0.01). Thus, co-culture
with M1 macrophages had less of an impact on the transcriptome of A/J than WT myoblasts (Fig. 6b).
Ingenuity Pathway Analysis led to the identification of
the major transcriptional networks that were differentially
regulated in WT myoblasts co-cultured with M1 macrophages. The major upregulated networks included the proinflammatory NFκB, IL-1β, TNFα, and TGFβ1 networks
(Fig. 6c), while the major downregulated networks were

Dysferlin-deficient macrophages show enhanced IL-10
and IL-12 expression

Our analyses suggested that the observed antimyogenic effects of M1 macrophages and promyogenic effects of M2a macrophages are mediated by
soluble factors secreted from each respective phenotype. Thus, we sought to identify the factors mediating
the effects on muscle differentiation in the co-cultures.
The marked differences of WT and Bla/J macrophages
on myoblast differentiation might be due to intrinsic differences in cytokine secretion. We focused on comparing
two key factors in the co-cultures: IL-12 secreted in response to LPS (M1) stimulation and IL-10 secreted in response to LPS+OVA-IC (M2b). ELISA analysis performed
on supernatants from 3-day-old co-cultures showed that
Bla/J macrophages released more IL-10 than WT in response to LPS (P < 0.001) and LPS+OVA-IC (P < 0.05)
stimulation and more IL-12 in response to LPS (P < 0.01)
and LPS+OVA-IC (P < 0.01) stimulation (Fig. 5a, b).
These data demonstrate that Bla/J macrophages release
more pro-inflammatory cytokines.
Finally, we used cytokine arrays to analyze the soluble
factors released into the culture medium after 3 days
of WT myoblast co-culture. Analysis of conditioned
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Fig. 5 Cytokines secreted in myoblast-macrophage co-cultures. ELISA analysis of 3-day old WT co-culture supernatants showing expression of
IL-10 (a) and IL-12 (b) in differentially polarized macrophages from WT (black bars) or Bla/J (white bars) mice. c Cytokine arrays performed on
supernatants of 3-day-old WT myoblasts co-cultured without macrophages (white) or with WT mice-derived Mϕ (black), M1 (light grey), or M2a
(dark grey) macrophages showing expression of M1-specific cytokines. d MSD IL-4 assay performed on supernatants of 1-day-old WT (white) or
A/J (black) myoblasts that were either cultured alone (none) or co-cultured with WT mice-derived M1 or M2a macrophages. Data are shown
as means ± SEM. n = 3; *P < 0.05; **P < 0.01; ***P < 0.001

muscle-specific networks including MyoD1, myogenin, and
Pax7 (Fig. 6c). We had previously shown that gene expression of Il1β is increased in dysferlin-deficient A/J myoblasts [21]. Consistent with the prior report, Il1β was
upregulated by 3.0-fold (P < 0.001) in untreated A/J compared with untreated WT myoblasts. Moreover, the IL-1β,
NFκB, TNFα, and TGFβ1 networks were less affected in
M1-co-cultured A/J myoblasts than in WT, consistent with
those networks being intrinsically upregulated in untreated
A/J myoblasts (Fig. 6c). Partek clustering analysis also
showed that untreated A/J myoblasts clustered with, i.e.,
were more similar to, WT myoblast-M1 macrophage cocultures rather than untreated WT myoblasts (Fig. 6e). Coculture of WT myoblasts with M1 macrophages led to significant upregulated expression of pro-inflammatory genes
including C2, Csf1, Ifitm1, Tnfaip2, and Tlr2 (Fig. 6e,
Table 2). Conversely, co-culture of WT myoblasts with M1
macrophages led to decreased expression of muscle
differentiation-specific genes, including Actn3, Igf1, Myoz2,
and Myh7 (Fig. 6e, Table 2). In contrast to WT, proinflammatory genes were upregulated, and muscle differentiation genes were downregulated, in untreated A/J
myoblasts, compared with untreated WT myoblasts, and
incubation with M1 macrophages did not further modify
their expression (Fig. 6e, Table 2). These data suggest that

intrinsically upregulated pro-inflammatory networks in
A/J muscle cultures are resistant to further activation
by co-culture with M1 macrophages.
Co-culture of WT myoblasts with M2a macrophages
activated muscle-specific, and inhibited inflammatory,
networks (Fig. 6d). Interestingly, muscle-specific networks including Rb1 and Cdkn2a were activated to a
greater extent in A/J than WT myoblasts when cocultured with M2a macrophages. Moreover, several
pro-inflammatory networks, including NFκB, IL-6, and
IL-1β, that were initially higher in untreated A/J than
WT myoblasts, were decreased to a greater extent than
WT when co-cultured with M2a macrophages (Fig. 6d).
Further, clustering analysis showed that co-culture of
A/J cells with M2a macrophages “ameliorated” their
characteristic pro-inflammatory phenotype by downregulating expression of pro-inflammatory genes, including Tnfsf9, Irf1, C2, and Il1b, and up-regulating the
expression of muscle-specific genes, including Myoz1,
Myl2, Myh6, Myf6, and Musk. Thus A/J myoblast-M2a
macrophage co-cultures clustered closely with, i.e., were
more similar to, both untreated WT myoblasts and WT
myoblast-M2a macrophage co-cultures (Fig. 6f, Table 3).
These analyses support the idea that M2a macrophages
(or factors released from them) may improve the
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(See figure on previous page.)
Fig. 6 Illumina Gene array analysis of myoblasts co-cultured with macrophages. Venn diagrams showing gene subsets in WT (a) or A/J (b) myoblasts
that were differentially regulated by co-culture with M1 only (green), by M2a only (red), or in both co-cultures (overlap). ANOVA, P < 0.01. Transcriptional
networks activated by co-culture with M1 (c) or M2a (d) in A/J (red) and WT (blue) myoblasts sorted by z-score. z-score >1.5 or <1.5 indicates activated
and inhibited networks, respectively. e, f Partek clustering analysis showing genes expressed in WT control myoblasts, A/J control myoblasts and WT or
A/J myoblasts co-cultured with M1 (e), or M2a (f). Blue indicates downregulated; red indicates upregulated

differentiation of dysferlin-deficient muscle cells by inhibiting the intrinsic pro-inflammatory environment that
is characteristic of dysferlin-deficient muscle.
The data from the desmin staining and transcriptome
analyses suggested a blunted response in A/J myoblasts
to co-culture with M1 macrophages, suggesting that A/J
myoblasts may be less sensitive than WT to the proinflammatory effects of M1 macrophages. We tested this
idea by examining NFκB pathway activation in lysates
of WT and A/J myoblasts co-cultured with M1 macrophages (Fig. 7). In accord with the transcriptome analysis, co-culture of WT myoblasts with M1 macrophages
led to robust phosphorylation of the NFκB-p65 subunit
(phospho-p65) (Fig. 7a, b), whereas phospho-p65, which
was significantly upregulated in untreated A/J cultures,
was not further augmented by co-culture with either
Mϕ or M1 macrophages (Fig. 7a, b).
The transcriptome analysis showed that IL-1β gene expression is upregulated in A/J myoblasts. Therefore, we
tested for expression of IL-1β protein in lysates of WT
and dysferlin-deficient co-cultured myotubes using an
ELISA assay that detects both the precursor and mature
forms of IL-1β. When WT myoblasts were co-cultured
with M2a macrophages, they expressed low levels of IL-1β
but showed significant upregulation of cellular IL-1β when
co-cultured with M1 macrophages. Compared with WT
myoblasts, expression of IL-1β in A/J myoblasts was significantly upregulated in M2a macrophage co-cultures
and was not further enhanced in M1 macrophage cocultured myotubes (Fig. 7c). We further tested IL-1β secretion into the co-culture supernatants and found that
M1 macrophage co-cultures secreted IL-1β at higher
levels compared with untreated or M2a macrophage cocultures, consistent with previous reports [30]. Furthermore, A/J myoblast-M1 macrophage co-cultures secreted
more IL-1β when compared with WT myoblast-M1
macrophage co-cultures (Fig. 7d).
IL-4 potentiates muscle differentiation in both WT and
A/J myoblasts

The major M2a macrophage-secreted cytokine identified
in our cytokine analyses, IL-4, has previously been implicated in playing an important role in myoblast differentiation, and its loss results in smaller myotubes with fewer
myonuclei [31]. However, the effect of IL-4 on myogenic
differentiation of dystrophic muscle has not been previously explored. Based on the above studies, we

hypothesized that IL-4 might be the soluble factor mediating the beneficial effects of M2a co-culture on A/J
myoblasts. To test this possibility, we queried whether
IL-4 alone can mirror the beneficial effects of A/J
myoblast-M2a macrophage co-culture, by potentiating
differentiation. Treatment with 20 ng/ml of IL-4 nearly
doubled the percent fusion, compared with untreated, in
both WT (43.0 ± 0.8 vs. 26.1 ± 2.9 %, P < 0.01) and A/J
(38.0 ± 6.0 vs. 15.7 ± 0.1 %, P < 0.05) cultures (Fig. 8a,
b). Treatment with lower amounts of IL-4 (4 ng/ml) also
showed a trend for increase, though not significant.
Additionally, treatment with IL-4 potentiated gene expression of MyoD, Myf5, and myogenin in WT muscle
cultures (Fig. 8c–e). IL-4 also increased the expression
of MyoD, Myf5, and myogenin genes in A/J cultures, but
not to the levels observed in WT cultures (Fig. 8c–e).
Thus, IL-4 alone is not sufficient to restore the muscle
differentiation defect in A/J myoblasts.
Inhibition of IL-1β ameliorates muscle differentiation in
A/J myoblasts

Having shown that IL-4 activity alone is not sufficient
to rescue muscle differentiation in A/J muscle cells,
we next focused on factors released from M1 macrophages that inhibit muscle differentiation. We initially
examined differentiation in cultures treated with the
pro-inflammatory cytokines we observed being released by M1 macrophages: IL-10, IL-12, and TNFα,
but did not observe any effects on myotube fusion.
We were then guided by our transcriptome analysis
of co-cultured myoblasts which revealed increased expression of the IL-1β gene in A/J myoblasts (Table 2),
as well as our observations of increased cellular and
secreted IL-1β protein in A/J myoblasts (Fig. 7c), and
qRT-PCR data showing that IL-1β is upregulated
in vivo in uninjured Bla/J muscle (Fig. 2). This, together with our previous demonstrations that IL-1β is
a major pro-inflammatory factor released from LPS/
BzATP-stimulated macrophages [30], and that A/J
muscle shows upregulated IL-1β secretion and IL-1β
signaling [30, 21] heavily implicated IL-1β in the suppression of muscle differentiation and has not been
previously reported. To test this idea in vitro, we
treated differentiating WT and A/J myoblasts with
recombinant IL-1β for 5 days. Treatment with IL-1β
reduced the percent fusion and the number of MyoDpositive cells, compared with untreated (Fig. 9a, b).
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Table 2 Transcripts modulated in A/J vs. WT myoblasts co-cultured with M1 macrophages
Gene symbol

Description

WT-M1 vs. WT

AJ vs. WT

AJ-M1 vs. AJ

Ifi27

Interferon, alpha-inducible protein 27

16.32

2.41

17.75

Ifit3

Interferon-induced protein with tetratricopeptide repeats 3

10.49

1.75

3.44

C2

Complement component 2

2.88

2.63

n/a

Ifitm1

Interferon-induced transmembrane protein 1

2.86

1.76

n/a

MMP2

Matrix metallopeptidase 2

2.77

2.54

n/a

IL7

Interleukin 7

2.62

1.69

n/a

H2-T23

Histocompatibility 2, T region locus 23

2.56

4.41

n/a

Ifitm3

Interferon-induced transmembrane protein 3

2.50

1.65

n/a

Vdr

Vitamin D (1,25-dihydroxyvitamine D3) receptor

2.37

2.18

n/a

Tnfaip2

Tumor necrosis factor, alpha-induced protein 2

2.28

1.57

n/a

Csf1

Colony stimulating factor 1

2.25

1.81

n/a

CCL9

Chemokine (C-C motif) ligand 9

2.23

1.99

2.79

Ltbp1

Latent transforming growth factor beta binding protein 1

2.20

1.53

n/a

Pde4b

Phosphodiesterase 4B, cAMP-specific

2.14

1.61

1.73

H2-Q5

Histocompatibility 2, Q region locus 5

2.00

2.63

n/a

Slc1a3

Solute carrier family 1 (glial high affinity glutamate transporter), member 3

1.99

5.59

n/a

Angptl4

Angiopoietin-like 4

1.98

1.93

n/a

Gch1

GTP cyclohydrolase 1

1.94

2.48

3.14

Bdnf

Brain-derived neurotrophic factor

1.93

1.54

n/a

P2rx4

Purinergic receptor P2X, ligand-gated ion channel 4

1.86

1.82

n/a

Tgif1

TGFB-induced factor homeobox 1

1.82

2.38

n/a

Serpinh1

Serpin peptidase inhibitor, clade H (heat shock protein 47)

1.76

1.53

1.64

Stat1

Signal transducer and activator of transcription 1

1.67

1.77

−1.72

Ccnd1

Cyclin D1

1.64

1.57

1.66

Dab2

Disabled 2, mitogen-responsive phosphoprotein

1.62

1.79

n/a

Nfkbie

Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon

1.60

n/a

1.54

Tlr2

Toll-like receptor 2

1.58

1.75

n/a

Bmpr2

Bone morphogenetic protein receptor, type II

1.50

1.58

n/a

Actn3

Actinin, alpha 3

−1.50

−1.50

n/a

Tlr4

Toll-like receptor 4

−1.53

n/a

−1.56

Rgs16

Regulator of G-protein signaling 16

−1.54

−1.64

n/a

Dpp3

Dipeptidyl-peptidase 3

−1.56

−1.63

n/a

Myh7

Myosin, heavy chain 7 (type I)

−1.65

−1.87

n/a

Id1

Inhibitor of DNA binding 1

−1.72

−1.53

−1.59

IL1b

Interleukin 1 beta

−1.73

3.05

−2.89

Cdkn1c

Cyclin-dependent kinase inhibitor 1C (p57, kip2)

−1.75

−18.10

2.61

Mef2c

Myocyte enhancer factor 2C

−1.80

−1.86

−2.27

Btrc

Beta-transducin repeat containing E3 ubiquitin protein ligase

−1.89

−1.50

n/a

Igf1

Insulin-like growth factor 1

−1.91

−1.71

n/a

Tgfb1

Transforming growth factor, beta 1

−1.96

1.58

−2.56

Tgfb2

Transforming growth factor, beta 1

−2.00

n/a

−1.84

Musk

Muscle, skeletal, receptor tyrosine kinase

−2.03

−4.73

−1.90

Myoz2

Myozenin 2

−2.88

−1.68

n/a

Sgcg

Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein)

−3.01

−1.83

−1.72
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Table 2 Transcripts modulated in A/J vs. WT myoblasts co-cultured with M1 macrophages (Continued)
Myl3

Myosin, light chain 3, skeletal slow

−3.07

−2.42

−1.53

Myf6

Myogenic factor 6

−4.13

−3.53

−1.94

Myh1

Myosin, heavy chain 1 (type IIx/d)

−5.89

1.91

n/a

Fold-change values of Illumina Gene array transcript subset which showed significant modulation by WT-M1 co-culture vs. WT alone compared to their fold-change
values in A/J vs. WT and A/J-M1 co-culture vs. A/J alone. Only transcripts with fold-change values >1.5 and P values <0.01 were considered for analysis. ANOVA was
applied to verify significance

Importantly, the decrease in myotube fusion and
MyoD-positive cell number was significantly greater
in A/J than WT cultures, indicating that A/J myoblasts are more sensitive than WT to IL-1β-mediated
inhibition of muscle differentiation (Fig. 9a, b). These
data suggest that IL-1β is the major M1 macrophagederived factor that inhibits differentiation of A/J
myoblasts.
Having identified upregulated IL-1β signaling in A/J
myoblasts, and inhibition of myogenesis due to IL-1β secreted from M1 macrophages in Bla/J muscle, we hypothesized that if IL-1β is mediating the defective
myogenesis and regeneration in dysferlin-deficiency,
then this effect should be blocked by inhibition of IL-1β
in muscle cultures. Differentiating WT and A/J myoblast
cultures were treated with an anti-IL-1β monoclonal
antibody (mAb) or equimolar concentrations of a control anti-mouse IgG. Treatment with the anti-IL-1β
mAb significantly increased myotube fusion (Fig. 9c, d),
the number of MyoD-positive cells (Fig. 9e), and expression of MyoD, Myf5, and myogenin (Fig. 9f–h) in A/J
muscle cultures, compared with control IgG treatment,
indicating that suppression of IL-1β signaling arising
from M1 macrophages can restore muscle regeneration
in dysferlin deficiency.

Discussion
Upregulated pro-inflammatory signaling in dysferlindeficient myoblasts inhibits muscle differentiation and
regeneration

Dysferlin-deficient muscle is marked by inflammatory
foci, mononuclear infiltrate, and upregulated NFκB pathway signaling [32, 33]. Mounting evidence suggests that
the upregulated IL-1β [30] and upregulated NFκB signaling [21] arises not only from immune cells but also from
dysferlin-deficient muscle fibers and cells. But whether
the inflammation impedes regeneration, and if so, what
aspect of it, has been in debate. Here, we present a
systematic evaluation of interactions between muscle
and macrophage cells to identify key factors mediating
the pro- and anti-myogenic response to macrophages
in dystrophic muscle. We used the approach of
macrophage-myoblast Transwell co-cultures to show
that M1-polarized macrophages, acting in part via IL-1β,
activate pro-inflammatory networks in WT myoblasts,
which greatly diminishes myoblast differentiation (Fig. 4).

In contrast, M2a macrophages, acting in part via IL-4,
potentiate muscle regeneration, especially in A/J myoblasts. In addition, we show that the intrinsically upregulated pro-inflammatory networks in dysferlin-deficient
muscle make it refractory to the myogenic inhibition by
M1 macrophages.
There has been some debate about whether loss of
dysferlin results in impaired regeneration. Earlier reports
suggested that muscle regeneration after crush injury in
SJL/J mice was faster than in BALB/c [34]. Examination
of notexin-induced injury in C57Bl10-SJL/J mice concluded that neutrophil recruitment was attenuated, but
muscle regeneration was unchanged [35]. More recently,
experiments using large-strain injury suggested that A/J
mice showed no attenuation in either neutrophil or
macrophage infiltration [36]. On the other hand, work in
our laboratory and others demonstrated that dysferlindeficient mice lag in muscle regenerative capacity, compared with dysferlin-sufficient [21, 37, 38]. It is possible
that differences in strains and types of injury could account for these discrepancies. Very little muscle pathology was observed in both native and C57Bl10-backcrossed SJL/J mice, which we posited could account for
the lack of observation of any regeneration defect, and
A/J mice lack complement C5 [17]. Thus, to rule out
confounding strain-specific effects unrelated to loss of
dysferlin, we conducted our experiments in Bla/J mice
compared with C57Bl/6J.
Our findings that regeneration after notexin injury in
Bla/J mice is attenuated and does not adequately resolve
accords with the conclusions of Chiu et al., although the
attribution of this outcome to a defect in neutrophil recruitment rather than monocyte recruitment does not
marry with our data. We show that M1 macrophages,
although upregulated in uninjured dysferlin-deficient
muscle, are not recruited as robustly as in WT muscle,
with fewer F4/80-positive cells observed by immunofluorescence staining (Fig. 3) throughout the course of recovery. Although we did not test for neutrophil recruitment,
our studies suggest that the M1-mediated response to injury is attenuated in Bla/J muscle, which we attribute to
chronic M1 macrophage infiltration and upregulation of
M1-derived IL-1β and NFκB in the absence of dysferlin.
The attenuated response to M1 macrophage recruitment in Bla/J mice could impede necrotic tissue clearing
in dysferlin-deficient muscle and thus be inhibitory to
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Table 3 Transcripts modulated in A/J vs. WT myoblasts co-cultured with M2a macrophages
Gene symbol

Description

WT-M2 vs. WT

AJ vs. WT

AJ-M2 vs. AJ

Myl2

Myosin, light polypeptide 2, regulatory, slow

2.31

n/a

3.07

Sdc4

Syndecan 4

2.04

−2.16

n/a

Nrap

Nebulin-related anchoring protein

1.98

n/a

2.29

Calr

Calreticulin

1.88

n/a

−1.87

Mylk2

Myosin light chain kinase 2

1.88

n/a

n/a

Ltbp1

Latent transforming growth factor beta binding protein 1

1.85

1.54

n/a

Ckm

Creatine kinase, muscle

1.83

n/a

1.78

Mybpc2

Myosin binding protein C, fast type

1.64

2.47

1.94

Rhob

Ras homolog family member B

1.62

n/a

1.58

Myh7

Myosin, heavy chain 7 (type I)

1.61

−1.87

n/a

Il4

Interleukin 4

1.59

n/a

n/a

Ryr1

Ryanodine receptor 1

1.57

n/a

n/a

Myoz2

Myozenin 2

1.56

−1.69

1.81

Myh6

Myosin, heavy chain 7 (cardiac)

1.52

n/a

2.00

Myom1

Myomesin 1

1.52

n/a

1.54

Id2

Inhibitor of DNA binding 2

−1.56

1.77

−2.20

Il7

Interleukin 7

−1.57

1.70

n/a

Rab27b

RAB27B, member RAS oncogene family

−1.61

n/a

−1.67

Iigp2

Interferon inducible GTPase 2

−1.79

2.06

−2.83

Psmb8

Proteosome subunit, beta type 8

−1.84

1.78

−1.86

Ifi47

Interferon gamma inducible protein 47

−1.90

2.18

−2.00

C2

Complement 2

−1.95

2.64

−2.40

Casp1

Caspase 1

−2.18

1.98

−2.22

Plk1

Polo-like kinase 1

−2.29

−2.76

−1.68

Irf1

Interferon regulatory factor 1

−2.91

1.88

−2.43

Gbp2

Guanylate binding protein 2, interferon-inducible

−3.37

1.60

−2.33

Akt2

v-akt murine thymoma viral oncogene 2

n/a

n/a

1.51

Gsk3B

Glycogen synthase kinase 3

n/a

n/a

−1.75

Itgb1

Integrin, beta 1 (fibronectin receptor beta)

n/a

n/a

−2.37

Jak1

Janus kinase 1

n/a

n/a

−1.87

Myoz1

Myozenin 1

n/a

n/a

1.70

Ripk1

Receptor (TNFRSF)-interacting serine-threonine kinase 1

n/a

n/a

−1.51

Vegfc

Vascular endothelial growth factor C

n/a

n/a

−1.50

Slc1a3

Solute carrier family 1 (glial high affinity glutamate transporter), member 3

n/a

5.59

−1.98

H2-T23

Histocompatibility 2, T region locus 23

n/a

4.41

−1.66

Il1b

Interleukin 1 beta

n/a

3.05

−2.47

Cxcl16

Chemokine (C-X-C motif) ligand 16

n/a

2.92

−1.74

Col5a2

Collagen, type V, alpha 2

n/a

2.66

−1.72

Crlf1

Cytokine receptor-like factor 1

n/a

2.64

−1.69

Ccl9

Chemokine (C-C motif) ligand 9

n/a

2.00

1.50

Angptl4

Angiopoietin-like 4

n/a

1.93

−1.52

Stat1

Signal transducer and activator of transcription 1

n/a

1.77

−1.61

Tnfrsf1b

Tumor necrosis factor receptor superfamily, member 1b

n/a

1.63

−1.51

Bmpr2

Bone morphogenetic protein receptor 2

n/a

1.58

−1.61
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Table 3 Transcripts modulated in A/J vs. WT myoblasts co-cultured with M2a macrophages (Continued)
Stam2

Signal transducing adaptor molecule (SH3 domain and ITAM motif) 2

n/a

1.57

−1.62

Gvin1

GTPase, very large interferon inducible 1

n/a

1.53

−1.75

Tnfsf9

Tumor necrosis factor (ligand) superfamily, member 9

n/a

1.51

−1.57

Prkaca

Protein kinase, cAMP-dependent, catalytic, alpha

n/a

−1.58

1.51

Prosapip1

ProSAPiP1 protein

n/a

−1.90

1.67

Myf6

Myogenic factor 6

n/a

−3.54

2.62

Musk

Muscle, skeletal, receptor tyrosine kinase

n/a

−4.73

−1.53

Cdkn1c

Cyclin-dependent kinase inhibitor 1C (p57, Kip2)

n/a

−18.11

5.52

Fold-change values of Illumina Gene array transcript subset which showed significant modulation by WT-M2a co-culture vs. WT alone compared to their foldchange values in A/J vs. WT and A/J-M2a co-culture vs. A/J alone. Only transcripts with fold-change values >1.5 and P values <0.01 were considered for analysis.
ANOVA was applied to verify significance

muscle regeneration. There have been substantial reports demonstrating that recruitment of neutrophils and
the removal of necrotic myofibers by M1 macrophages
is a pre-requisite to successful regeneration [14]. This
view is further substantiated by acute injury studies, in
which removal of phagocytes by use of liposomeencapsulated clodronate [39], depletion of CD11b
promoter-driven diphtheria toxin [13] or by use of a
Ly6C and Ly6G-blocking antibody [40], resulted in delayed regeneration, with ensuing increase in necrotic
myofibers, interstitial inflammation, and fat infiltration.
Whereas phagocytes are necessary for resolution of
acute injury, their role is less clear in chronic inflammatory disease; numerous studies have now documented
advantages of blocking some aspects of the inflammatory response to improve pathology, by inhibiting TLRs
in mdx [23] and dysferlin-deficient mice [41], and by depletion of complement C3 in dysferlin-deficient mice
[42]. Our studies suggest the specific depletion or blockade of inflammatory mediators, such as IL-1β, as an alternative strategy to take advantage of M1 macrophagemediated clearance without the subsequent immunopathology associated with their recruitment.
Macrophages from dysferlin-deficient muscle were
previously shown to be more phagocytic than WT [29].
We further characterized macrophages from Bla/J mice
as secreting excess IL-12 (M1 response) and IL-10 (M2b
response), which complements the earlier studies. Furthermore, undifferentiated macrophages from Bla/J mice
inhibited differentiation when co-cultured with WT
myoblasts. Together, these studies support the view that
dysferlin-deficient un-polarized bone marrow-derived
macrophages are “primed” towards the M1 phenotype.
Such “priming” is likely to be a result of DAMP signals in
dysferlin-deficient muscle (reviewed in [43, 8]). DAMP signals are recognized by TLR receptors which activate intracellular signaling pathways via the adaptor molecule,
myeloid differentiation primary response gene 88 (MyD88),
thus stimulating macrophage activation (reviewed in [43]).

Effects of differently polarized macrophages on muscle
regeneration

Previous characterization of interactions between
macrophages and myoblasts demonstrated that direct
co-culture with M1-polarized macrophages decreased
fusion of WT myoblasts [16]. Our observations using
the Transwell co-cultures of WT myoblasts and M1polarized macrophages show a similar inhibition of differentiation and are in agreement with those made in
the earlier study.
Alternatively, activated macrophages have been shown
to potentiate muscle growth. ED2+ macrophages selectively increase myoblast proliferation in muscle cultures
[44]. A more current classification identifies IL-4-activated
M2a macrophages as pro-myogenic, since direct coculture of myoblasts with M2a macrophages or M2aconditioned media increased myotube fusion and the
number of myogenin-positive cells [16]. In agreement
with these findings, our Transwell co-cultures with
M2a macrophages facilitated muscle differentiation of
dysferlin-deficient myoblasts (Fig. 4), fitting well with our
transcriptome analysis, which suggested that the improvement arises from upregulation of pro-myogenic molecular
networks in the myoblasts (Fig. 6).
Our particular advance was the identification of IL-4 as
the major factor mediating the pro-myogenic activity of
M2a macrophages. IL-4 has been documented as a potent
promoter of muscle growth. Treatment of muscle cultures
with IL-4 in vitro leads to myotube hypertrophy, whereas
mice lacking IL-4 or its receptor show reduced muscle
size [31]. IL-4 has been shown to inhibit secretion of IL1β, TNF, and IL-6 from monocytes [45], and when secreted following muscle damage, to inhibit differentiation
of adipocyte progenitor cells [12]; thus, the beneficial effect of IL-4 on A/J myoblast differentiation may be mediated by its anti-inflammatory and pro-myogenic activities.
These studies, together with our current observations, further substantiate the role of IL-4 as an important player
mediating muscle growth.
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Fig. 8 IL-4 potentiates muscle differentiation in WT and A/J myoblasts.
a Immunofluorescence staining of differentiated WT and A/J cultures
treated for 72 h with 4 or 20 ng/ml of IL-4. Control cultures were treated
with equal volumes of PBS (NT). Following incubation, cultures were
immunostained with anti-MyoD (green) and anti-MyHC (red). Scale bar,
50 μm. b Myofusion index (expressed as % fusion). c–e Gene expression
of MyoD (b), Myf5 (c), and myogenin (d) determined by qRT-PCR in WT
and A/J cultures treated with indicated concentrations of IL-4. N = 4.
Data are shown as means ± SEM. ANOVA with Tukey post hoc analysis,
*P < 0.05; **P < 0.01; ***P < 0.005

Fig. 7 NFκB and IL-1β in myoblast-macrophage co-cultures.
a Representative Western blot showing phosphorylation of the
NFκB p65 subunit in WT or A/J myoblasts either cultured alone
(-), or co-cultured for 3 days with Mϕ, or M1 macrophages.
b Quantitation of phospho-p65 pixel intensity in a, normalized
to vinculin pixel intensity. n = 3 independent experiments.
c IL-1β ELISA analysis of whole cell lysates prepared from WT
(black) or A/J myotubes (white) co-cultured for 24 h with M1 or
M2a macrophages. d MSD IL-1β assay performed on supernatants from
WT (black) or A/J myotubes (white) co-cultured for 24 h alone, with M1
or M2a macrophages. Two-way ANOVA with Tukey post hoc test were
used to calculate P values. n = 3 cultures per data point. Data are
shown as means ± SEM. *P < 0.05; ***P < 0.001

IL-1β negatively affects muscle regeneration

Co-culture with M1 macrophages had less of an impact
on the transcriptome of A/J than WT myoblasts (Fig. 6b),
which our data suggest is due to intrinsically upregulated expression of cytokines, such as IL-1β in the
A/J myoblasts. We have previously shown that dysferlindeficient muscle shows upregulated expression of the IL1β gene and protein [30, 21] and have now extended
these studies to include upregulated IL-1β gene expression in uninjured dysferlin-deficient muscle (Fig. 2), upregulated IL-1β gene expression in A/J myoblasts
(Table 2), increased IL-1β precursor and mature forms
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Fig. 9 Upregulated IL-1β inhibits muscle differentiation in A/J myoblasts. a Quantitation of myotube fusion in WT or A/J myoblasts treated with indicated
concentrations of IL-1β for 72 h. Percent myotube fusion was calculated from MyHC-positive immunostaining. b Quantitation of MyoD-positive cells are
shown as percent of total nuclei in WT or A/J myoblast cultures treated with indicated concentrations of IL-1β for 72 h. c Immunofluorescence staining of
myoblast cultures after treatment with an IL-1β blocking antibody (IL-1β mAb). WT and A/J cultures were plated at equal density and treated with 4 ng/ml
of IL-1β mAb for 72 h. Control cultures were treated with equimolar concentrations of mouse IgG. Fixed cultures were stained with anti-MyoD (green) and
anti-MyHC (red) antibodies. d Quantitation of myotube fusion in treated cultures. e Quantitation of MyoD-positive cells in treated cultures. f–h Gene
expression of MyoD (f), Myf5 (g), and myogenin (h) determined by qRT-PCR in cultures treated with indicated concentrations of IL-1β mAb. n = 3. Data are
shown as means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.005

in lysates (Fig. 7c), and supernatants from A/J myoblasts
co-cultured with M1 macrophages (Fig. 7d), compared
with WT myoblasts. Importantly, treatment with an IL1β mAb to neutralize IL-1β improved differentiation of
A/J myoblasts (Fig. 9). Together, these studies make a
compelling case for IL-1β as a major player mediating
the aberrant response to regeneration in dysferlin deficiency. The secreted form of IL-1β is produced from the
precursor pro-peptide by cleavage via the NALP-3 complex [30], a process requiring both a DAMP signal such
as LPS as well as an additional signal, such as benzylated
ATP (BzATP). LPS stimulation of Mϕ macrophages
without the BzATP also leads to release of IL-1β [30],

which we observed in our co-culture supernatants
(Fig. 7d), albeit at low levels, reflecting the short-lived
nature of secreted IL-1β. Both the pro-peptide and
mature forms of IL-1β are overproduced in dysferlindeficient muscle [30] where the second signal likely
arises from the dystrophic muscle milieu. The upregulated
IL-1β gene expression and pro-peptide production could
be a consequence of IL-12, which was secreted from M1
macrophages and upregulated in dysferlin-deficient M1
macrophages (Fig. 5). One possibility for the effectiveness
of the IL-1β mAb could be the prevention of an autocrine
response in which low levels of IL-1β stimulates its own
gene expression, as was recently reported in A431 cells

Cohen et al. Skeletal Muscle (2015) 5:24

[46]. Thus, treatment with the mAb IL-1β might block IL1β signaling and restore its own gene expression back
to baseline. However, how the loss of dysferlin results in
upregulated IL-1β and NFκB signaling in myoblasts
explanted from the pro-inflammatory environment of
dysferlin-deficient muscle remains unknown and will be
addressed in future studies.

Conclusions
We show for the first time that IL-1β is inhibitory
towards muscle differentiation, implicating IL-1β as the
factor accounting for attenuated muscle regeneration in
dysferlin-deficient muscle. We further show that blocking IL-1β leads to a marked improvement of muscle differentiation in vitro, suggesting that blockade of IL-1β
in vivo may be a therapeutic target for dysferlin deficiency. Several IL-1β blocking monoclonal antibodies
are currently being developed for autoimmune disorders
including rheumatoid arthritis, cryopyrin-associated
periodic syndrome, diabetes, and gout [47–49]. Our data
provides the first evidence that inhibiting IL-1β may improve muscle differentiation in dysferlin deficiency and
thus presents a novel therapeutic avenue for treating inflammatory myopathies.
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